Last reviewed · How we verify
DS-01
At a glance
| Generic name | DS-01 |
|---|---|
| Also known as | SEED synbiotic |
| Sponsor | Beth Israel Deaconess Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- SH-DS01 on Fecal Metagenomic Stability (PHASE2)
- Establishment and Clinical Application of Breast Cancer Risk Prediction Model Based on Traditional Chinese Medicine Four Diagnostic Instruments and Ultrasound
- Probiotics, Immune Function, and the Brain in Alcohol Consumers (PHASE2)
- Next-Gen MS: Feed-forward PRO Data for MS Research
- Probiotic and Antibiotic Therapies in Women With Unexplained Infertility (PHASE2)
- Metagenomic and Metabolomic Reconstitution of Gut Microbiota After Broad Spectrum Antibiotic Therapy (NA)
- Feasibility Study of Tumor Blood Flow Measurement by Detection of Positron Activation Post Proton Therapy (DS01)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DS-01 CI brief — competitive landscape report
- DS-01 updates RSS · CI watch RSS
- Beth Israel Deaconess Medical Center portfolio CI